US6703522B2 - Alkyl amino acid derivatives useful as pharmaceutical agents - Google Patents

Alkyl amino acid derivatives useful as pharmaceutical agents Download PDF

Info

Publication number
US6703522B2
US6703522B2 US10/301,295 US30129502A US6703522B2 US 6703522 B2 US6703522 B2 US 6703522B2 US 30129502 A US30129502 A US 30129502A US 6703522 B2 US6703522 B2 US 6703522B2
Authority
US
United States
Prior art keywords
compound
hydrogen
phenyl
methyl
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/301,295
Other versions
US20030144214A1 (en
Inventor
David Clive Blakemore
Justin Stephen Bryans
Sophie Caroline Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viatris Specialty LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Priority to US10/301,295 priority Critical patent/US6703522B2/en
Publication of US20030144214A1 publication Critical patent/US20030144214A1/en
Application granted granted Critical
Publication of US6703522B2 publication Critical patent/US6703522B2/en
Assigned to WARNER-LAMBERT COMPANY LLC reassignment WARNER-LAMBERT COMPANY LLC ARTICLES OF ORGANIZATION-CONVERSION Assignors: WARNER-LAMBERT COMPANY
Assigned to UPJOHN US 1 LLC reassignment UPJOHN US 1 LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WARNER-LAMBERT COMPANY LLC
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton

Definitions

  • This invention relates to novel alkyl amino acid derivatives useful as pharmaceutical agents, to processes for their production, to pharmaceutical compositions containing them, and to their use for the treatment of the neurological conditions set out below.
  • R 1 represents straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl or phenyl;
  • R 2 represents hydrogen or methyl
  • R 3 represents hydrogen, methyl or carboxyl.
  • the compounds are analogues of ⁇ -aminobutyric acid (GABA) and were stated to activate GAD, to bind to a novel binding site, to be useful in anti-seizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive diskinesia and spasticity, and also to exhibit antidepressant, anxiolytic and antipsychotic activity.
  • GABA ⁇ -aminobutyric acid
  • That compound is variously called 4-amino-3-(2-methylpropyl)butanoic acid, 3-(aminomethyl)-5-methylhexanoic acid, ⁇ -isobutyl- ⁇ -aminobutyric acid, isobutyl-GABA, isobutylgaba and pregabalin.
  • U.S. Pat. No. 6,001,876 discloses that the above compounds are useful in pain therapy.
  • U.S. Pat. No. 5,840,956 discloses methods for making ( ⁇ )-isobutylgaba and for obtaining from it (S)-isobutylgaba. The disclosures of all the above patents are hereby incorporated by reference.
  • a problem with which this invention is concerned is the production of compounds useful in the manner of pregabalin, especially in pain therapy, that when administered to humans or other animals provide an increased duration of active ingredient in the plasma.
  • P is hydrogen or methyl
  • Q is a labile amine- or amide-forming organic group that becomes removed in the human or animal body
  • R 1 is straight or branched C 2 -C 6 alkyl, C 3 -C 6 cycloalkyl or phenyl;
  • R 2 is hydrogen or methyl
  • R 3 is hydrogen, methyl or carboxyl
  • R 4 is hydrogen or a labile ester-forming group selected from substituted and unsubstituted C 1 -C 6 alkyl, benzyl and phenyl groups that become removed in the human or animal body, and
  • R 1 is phenyl and R 2 , R 3 and R 4 are each hydrogen.
  • a pro-drug of the above formula when administered to a human or other animal, especially a mammal, enters the bloodstream by passive diffusion along the whole length of the intestine, which gives a much longer duration of effectiveness.
  • the pro-drug may not itself be biologically active, but decomposes to the corresponding active compound in plasma.
  • Certain of the compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.
  • the solvated forms, including hydrated forms are biologically equivalent to unsolvated forms and are encompassed within the scope of the invention.
  • Certain of the compounds of the invention possess one or more chiral centers and each center may exist in the R or S configuration.
  • the invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. It also includes salts of any of the above compounds with physiologically acceptable cations or anions.
  • the invention also provides a method for making a compound of the formula (III) above, which comprises:
  • the invention also provides a method for making a compound of the formula (III) above, which comprises coupling a compound of the formula (V) that is a carboxylic acid, optionally employing the further step of esterifying the carboxyl group with a substituted or unsubstituted C 1 -C 6 alkanol, benzyl alcohol or phenol.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (III) above and a pharmaceutically acceptable carrier.
  • the invention provides the use of a compound of formula (III) in the manufacture of a medicament for the treatment of any of the following:
  • epilepsy a faintness attack; hypokinesia; a cranial disorder; a neurodegenerative disorder; depression; anxiety; panic; pain; a neuropathological disorder; a digestive disorder.
  • the invention provides a method for treating any of the above disorders which comprises administering a therapeutically effective amount of a compound of formula (III) to a human or animal in need of said treatment.
  • One class of pro-drugs of the invention which is preferred on account of the relatively high activity of the parent compound, comprises isobutylgaba pro-drugs of the formula (IV)
  • R 4 is not hydrogen, it is desirable that it should be more labile than Q so that under physiological conditions the free acid forms first and unwanted reactions between the amino and carboxyl groups are avoided.
  • Suitable values of R 4 other than hydrogen are ethyl, iso-propyl, benzyl, phenyl, methyl and t-butyl.
  • the group Q may be one which can be removed hydrolytically under physiological conditions, in which case it may be
  • R 5 is hydrogen, straight or branched chain C 1 -C 6 alkyl, phenyl or benzyl in which the benzene ring may be substituted or unsubstituted;
  • Y is hydrogen, straight or branched chain C 1 -C 6 alkyl, or —CH 2 CO 2 R 6 in which R 6 represents straight or branched chain C 1 -C 6 alkyl
  • the group Q may be one which can be removed enzymatically under physiological conditions, in which case it may be selected from
  • R 7 is hydrogen, straight or branched chain, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted;
  • X represents a phenyl group or any of the side chains of the 20 naturally encoded ⁇ -amino acids.
  • R 7 is C 1 -C 6 alkyl (preferably methyl or t-butyl) or phenyl.
  • amide prodrugs of pregabalin may be prepared by reacting pregabalin with an acid chloride in an ether e.g. tetrahydrofuran at ambient temperatures.
  • a carboxylic acid group of the resulting prodrug may be converted to an ester group by reaction with an alcohol e.g. by reaction with benzyl alcohol in the presence of 1,3-dicyclohexyldiimide (DCC) and 4-dimethylaminopyridine (DMAP) in a halogenated hydrocarbon solvent e.g. dichloromethane (DCM) at ambient temperatures.
  • DCC 1,3-dicyclohexyldiimide
  • DMAP 4-dimethylaminopyridine
  • (Acyloxy)alkyl carbamate prodrugs of pregabalin may be prepared by reacting pregabalin with an acyloxyalkyl p-nitrophenyl carbonate in an ether e.g. tetrahydrofuran at ambient temperatures.
  • the compounds of the invention are expected to be useful in the treatment of epilepsy. They may also be used as mimetic agents for neurodegenerative disorders. Such neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.
  • the present invention also covers treating acute brain injury. These include but are not limited to: stroke, head trauma, and asphyxia. Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal and global ischemia.
  • CVA cerebral vascular incident
  • transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia such as in a patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like.
  • Other incidents are head trauma, spinal cord trauma, or injury from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embole, hyperfusion, and hypoxia.
  • Treatment with the present compounds could also be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.
  • a skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as suffering from stroke for administration by methods of the present invention.
  • the compounds of the invention are also expected to be useful in the treatment of depression.
  • Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression.
  • the diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt.
  • the standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to as the DSM-IV-R manual published by the American Psychiatric Association, 1994.
  • the present compounds are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures.
  • Pain refers to acute as well as chronic pain.
  • Acute pain is usually short-lived and is associated with hyperactivity of the sympathetic nervous system. Examples are postoperative pain and allodynia.
  • Chronic pain is usually defined as pain persisting from 3 to 6 months and includes somatogenic pains and psychogenic pains. Other pain is nociceptive.
  • Still other pain is caused by injury or inflammation of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis.
  • Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies.
  • Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from.
  • Psychogenic pain is that which occurs without an organic origin such as low back pain, atypical facial pain, and chronic headache.
  • inflammatory pain osteoarthritic pain
  • trigeminal neuralgia cancer pain
  • diabetic neuropathy restless leg syndrome
  • acute herpetic and postherpetic neuralgia causalgia
  • brachial plexus avulsion occipital neuralgia
  • gout phantom limb
  • burn and other forms of neuralgia, neuropathic and idiopathic pain syndrome.
  • the present compounds are also expected to be useful in the treatment of digestive disorders such as visceral pain, pain associated with cancer, the irritable bowel syndrome, infection and inflammation.
  • the present compounds can be prepared and administered in a wide variety of oral and parenteral dosage forms.
  • they can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally.
  • they can be administered by inhalation, for example, intranasally.
  • the compounds of the present invention can be administered transdermally.
  • the following dosage forms may comprise as the active component either a compound of the invention or a corresponding pharmaceutically acceptable salt.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid that is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl-cellulose, a low melting wax, cocoa butter, and the like.
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.
  • the pharmaceutical preparation is preferably in unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component.
  • the drug may be administered three times daily as, for example, capsules of 100 or 300 mg.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • the compounds utilised in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily.
  • a daily dose range of about 0.01 mg to about 100 mg/kg is preferred.
  • the dosages may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
  • Carbonate 1 was prepared as described in J.Med.Chem, 1988, 31, 318-322 (5.29 g, 98%). Its characteristics were described in J.Org.Chem, 1997, 62, 1356-1362.
  • Carbonate 2 was also prepared as described in the above paper (1.16 g, 60%).
  • Carbonate 3 was also prepared as described in the above paper (1.76 g, 85%).
  • Benzoyl chloride (0.88 ml, 7.6 mmol) was added to a stirred suspension of pregabalin (1.0 g, 6.3 mmol) in THF (80 ml) at room temperature under argon and the reaction mixture was stirred for 18 hours. The reaction mixture was then filtered and concentrated in vacuo. The residue was chromatographed (SiO 2 , heptane-ethyl acetate, 1:1 to 3:7) to give 4 (0.78 g, 47%).
  • the carbonate 1 (1.0 g, 3.9 mmol) and pregabalin (0.62 g, 3.9 mmol) were stirred in THF (60 ml) at room temperature for 48 hours.
  • the reaction mixture was taken up in ethyl acetate (250 ml) and washed with water (200 ml), 1N HCl (200 ml), dried (MgSO 4 ) and concentrated in vacuo.
  • the residue was purified by column chromatography (SiO 2 , heptane, then heptane-ethyl acetate, 1:1) to give (6) (0.18 g, 17%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III)
Figure US06703522-20040309-C00001
In the above formula:
P represents hydrogen or methyl;
Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body;
R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;
R2 represents hydrogen or methyl; and
R3 represents hydrogen, methyl or carboxyl; and
R4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen. Pharmaceutically acceptable salts of any salt-forming compound within the above class are also included. The compounds may be used to treat a range of neurological conditions, e.g. epilepsy and pain.

Description

This is a continuation of application Ser. No. 09/920,215 filed Aug. 1, 2001 now abandoned.
FIELD OF THE INVENTION
This invention relates to novel alkyl amino acid derivatives useful as pharmaceutical agents, to processes for their production, to pharmaceutical compositions containing them, and to their use for the treatment of the neurological conditions set out below.
BACKGROUND TO THE INVENTION
U.S. Pat. No. 5,563,175 describes compounds of the formula (I)
Figure US06703522-20040309-C00002
in which:
R1 represents straight or branched C1-C6 alkyl, C3-C6 cycloalkyl or phenyl;
R2 represents hydrogen or methyl; and
R3 represents hydrogen, methyl or carboxyl.
The compounds (including their pharmaceutically acceptable salts) are analogues of γ-aminobutyric acid (GABA) and were stated to activate GAD, to bind to a novel binding site, to be useful in anti-seizure therapy for central nervous system disorders such as epilepsy, Huntington's chorea, cerebral ischemia, Parkinson's disease, tardive diskinesia and spasticity, and also to exhibit antidepressant, anxiolytic and antipsychotic activity. The most preferred compounds were those where R3 and R2 were hydrogen and R1 was isobutyl, the (S)-(+) enantiomer of formula (II) being the most preferred.
Figure US06703522-20040309-C00003
That compound is variously called 4-amino-3-(2-methylpropyl)butanoic acid, 3-(aminomethyl)-5-methylhexanoic acid, β-isobutyl-γ-aminobutyric acid, isobutyl-GABA, isobutylgaba and pregabalin.
U.S. Pat. No. 6,001,876 discloses that the above compounds are useful in pain therapy. U.S. Pat. No. 5,840,956 discloses methods for making (±)-isobutylgaba and for obtaining from it (S)-isobutylgaba. The disclosures of all the above patents are hereby incorporated by reference.
SUMMARY OF THE INVENTION
A problem with which this invention is concerned is the production of compounds useful in the manner of pregabalin, especially in pain therapy, that when administered to humans or other animals provide an increased duration of active ingredient in the plasma.
That problem is unexpectedly solved, according to the invention, by pro-drugs of pregabalin the compounds of the formula (III)
Figure US06703522-20040309-C00004
in which:
P is hydrogen or methyl;
Q is a labile amine- or amide-forming organic group that becomes removed in the human or animal body;
R1 is straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;
R2 is hydrogen or methyl; and
R3 is hydrogen, methyl or carboxyl;
R4 is hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body, and
a pharmaceutically acceptable salt of any salt-forming compound within the above class,
but excluding compounds in which R1 is phenyl and R2, R3 and R4 are each hydrogen.
It is believed that a pro-drug of the above formula when administered to a human or other animal, especially a mammal, enters the bloodstream by passive diffusion along the whole length of the intestine, which gives a much longer duration of effectiveness. The pro-drug may not itself be biologically active, but decomposes to the corresponding active compound in plasma.
Certain of the compounds of the invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are biologically equivalent to unsolvated forms and are encompassed within the scope of the invention. Certain of the compounds of the invention possess one or more chiral centers and each center may exist in the R or S configuration. The invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. It also includes salts of any of the above compounds with physiologically acceptable cations or anions.
The invention also provides a method for making a compound of the formula (III) above, which comprises:
coupling a compound of the formula:
Figure US06703522-20040309-C00005
in which P and R1-R4 have the meanings given above and in which said compound is in the form of a free base or an ammonium salt with a compound of the formula (VI)
Figure US06703522-20040309-C00006
or QCl, where (in each case) Q has the meaning given above;
and the invention also provides a method for making a compound of the formula (III) above, which comprises coupling a compound of the formula (V) that is a carboxylic acid, optionally employing the further step of esterifying the carboxyl group with a substituted or unsubstituted C1-C6 alkanol, benzyl alcohol or phenol.
The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (III) above and a pharmaceutically acceptable carrier.
In a further aspect the invention provides the use of a compound of formula (III) in the manufacture of a medicament for the treatment of any of the following:
epilepsy; a faintness attack;
hypokinesia; a cranial disorder;
a neurodegenerative disorder; depression;
anxiety; panic;
pain; a neuropathological disorder;
a digestive disorder.
In a further aspect, the invention provides a method for treating any of the above disorders which comprises administering a therapeutically effective amount of a compound of formula (III) to a human or animal in need of said treatment.
DESCRIPTION OF PREFERRED FEATURES
One class of pro-drugs of the invention, which is preferred on account of the relatively high activity of the parent compound, comprises isobutylgaba pro-drugs of the formula (IV)
Figure US06703522-20040309-C00007
in which P, Q and R4 have the meanings given above, and pharmaceutically acceptable salts of any salt-forming compound within the above class.
Where R4 is not hydrogen, it is desirable that it should be more labile than Q so that under physiological conditions the free acid forms first and unwanted reactions between the amino and carboxyl groups are avoided. Suitable values of R4 other than hydrogen are ethyl, iso-propyl, benzyl, phenyl, methyl and t-butyl.
The group Q may be one which can be removed hydrolytically under physiological conditions, in which case it may be
Figure US06703522-20040309-C00008
in which:
R5 is hydrogen, straight or branched chain C1-C6 alkyl, phenyl or benzyl in which the benzene ring may be substituted or unsubstituted; and
Y is hydrogen, straight or branched chain C1-C6 alkyl, or —CH2CO2R6 in which R6 represents straight or branched chain C1-C6 alkyl
Alternatively, the group Q may be one which can be removed enzymatically under physiological conditions, in which case it may be selected from
Figure US06703522-20040309-C00009
in which:
R7 is hydrogen, straight or branched chain, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and
X represents a phenyl group or any of the side chains of the 20 naturally encoded α-amino acids.
In a preferred group of compounds Q is
Figure US06703522-20040309-C00010
wherein R7 is C1-C6 alkyl (preferably methyl or t-butyl) or phenyl.
Compounds according to the invention include inter alia:
(S)-3-(Benzoylaminomethyl)-5-methylhexanoic acid;
(S)-Benzyl 3-(acylaminomethyl)-5-methylhexanoate;
(S)-3-[N-(acetoxymethyleneoxycarbonyl)aminomethyl]-5-methylhexanoic acid;
(S)-3-[N-((2,2-dimethylpropionyloxy)methyleneoxycarbonyl)-aminomethyl]-5-methylhexanoic acid;
(S)-3-[N-(benzoyloxymethyleneoxycarbonyl)aminomethyl]-5-methylhexanoicacid; and
pharmaceutically acceptable salts of any of the above.
Various methods may be used to prepare compounds according to the invention e.g. from starting materials disclosed in the patents referred to above.
For example, amide prodrugs of pregabalin may be prepared by reacting pregabalin with an acid chloride in an ether e.g. tetrahydrofuran at ambient temperatures. A carboxylic acid group of the resulting prodrug may be converted to an ester group by reaction with an alcohol e.g. by reaction with benzyl alcohol in the presence of 1,3-dicyclohexyldiimide (DCC) and 4-dimethylaminopyridine (DMAP) in a halogenated hydrocarbon solvent e.g. dichloromethane (DCM) at ambient temperatures. (Acyloxy)alkyl carbamate prodrugs of pregabalin may be prepared by reacting pregabalin with an acyloxyalkyl p-nitrophenyl carbonate in an ether e.g. tetrahydrofuran at ambient temperatures.
These reactions are illustrated in the following reaction scheme by reference to preferred reagents and preferred final products (4), (5) and (6), it being understood that a similar scheme applies mutatis mutandis to the use of other acyl chlorides, acyloxymethylene carbonates and optionally esterifying reagents, for the preparation of other final products of formula (III) above.
Figure US06703522-20040309-C00011
The compounds of the invention are expected to be useful in the treatment of epilepsy. They may also be used as mimetic agents for neurodegenerative disorders. Such neurodegenerative disorders are, for example, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The present invention also covers treating acute brain injury. These include but are not limited to: stroke, head trauma, and asphyxia. Stroke refers to a cerebral vascular disease and may also be referred to as a cerebral vascular incident (CVA) and includes acute thromboembolic stroke. Stroke includes both focal and global ischemia. Also, included are transient cerebral ischemic attacks and other cerebral vascular problems accompanied by cerebral ischemia such as in a patient undergoing carotid endarterectomy specifically or other cerebrovascular or vascular surgical procedures in general, or diagnostic vascular procedures including cerebral angiography and the like. Other incidents are head trauma, spinal cord trauma, or injury from general anoxia, hypoxia, hypoglycemia, hypotension as well as similar injuries seen during procedures from embole, hyperfusion, and hypoxia. Treatment with the present compounds could also be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus. A skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as suffering from stroke for administration by methods of the present invention.
The compounds of the invention are also expected to be useful in the treatment of depression. Depression can be the result of organic disease, secondary to stress associated with personal loss, or idiopathic in origin. There is a strong tendency for familial occurrence of some forms of depression suggesting a mechanistic cause for at least some forms of depression. The diagnosis of depression is made primarily by quantification of alterations in patients' mood. These evaluations of mood are generally performed by a physician or quantified by a neuropsychologist using validated rating scales, such as the Hamilton Depression Rating Scale or the Brief Psychiatric Rating Scale. Numerous other scales have been developed to quantify and measure the degree of mood alterations in patients with depression, such as insomnia, difficulty with concentration, lack of energy, feelings of worthlessness, and guilt. The standards for diagnosis of depression as well as all psychiatric diagnoses are collected in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) referred to as the DSM-IV-R manual published by the American Psychiatric Association, 1994.
The present compounds are also expected to be useful in the treatment of anxiety and of panic as demonstrated by means of standard pharmacological procedures.
The compounds of the invention are also expected to be useful in the treatment of pain. Pain refers to acute as well as chronic pain. Acute pain is usually short-lived and is associated with hyperactivity of the sympathetic nervous system. Examples are postoperative pain and allodynia. Chronic pain is usually defined as pain persisting from 3 to 6 months and includes somatogenic pains and psychogenic pains. Other pain is nociceptive. Still other pain is caused by injury or inflammation of peripheral sensory nerves. It includes, but is not limited to pain from peripheral nerve trauma, herpes virus infection, diabetes mellitus, causalgia, plexus avulsion, neuroma, limb amputation, and vasculitis. Neuropathic pain is also caused by nerve damage from chronic alcoholism, human immunodeficiency virus infection, hypothyroidism, uremia, or vitamin deficiencies. Neuropathic pain includes, but is not limited to pain caused by nerve injury such as, for example, the pain diabetics suffer from. Psychogenic pain is that which occurs without an organic origin such as low back pain, atypical facial pain, and chronic headache. Other types of pain are: inflammatory pain, osteoarthritic pain, trigeminal neuralgia, cancer pain, diabetic neuropathy, restless leg syndrome, acute herpetic and postherpetic neuralgia, causalgia, brachial plexus avulsion, occipital neuralgia, gout, phantom limb, burn, and other forms of neuralgia, neuropathic and idiopathic pain syndrome.
The present compounds are also expected to be useful in the treatment of digestive disorders such as visceral pain, pain associated with cancer, the irritable bowel syndrome, infection and inflammation.
The present compounds can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, they can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, they can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component either a compound of the invention or a corresponding pharmaceutically acceptable salt.
For preparing pharmaceutical compositions from the present compounds, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
In powders, the carrier is a finely divided solid that is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl-cellulose, a low melting wax, cocoa butter, and the like. The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted, and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents as desired.
Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilising agents, and the like.
The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 1 g according to the particular application and the potency of the active component. In medical use the drug may be administered three times daily as, for example, capsules of 100 or 300 mg. The composition can, if desired, also contain other compatible therapeutic agents.
In therapeutic use, the compounds utilised in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 100 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
Preparation of Reagents
Acetoxymethyl p-nitrophenyl Carbonate (1)
Figure US06703522-20040309-C00012
Carbonate 1 was prepared as described in J.Med.Chem, 1988, 31, 318-322 (5.29 g, 98%). Its characteristics were described in J.Org.Chem, 1997, 62, 1356-1362.
νmax(film)/cm−1 1776 (C═O), 1526 (C═C, Ar).
δH(400 MHz; CDCl3) 2.19 (3H, s, CH3), 5.88 (2H, s, OCH2O), 7.42 (2H, d, J 9.6, p-NO2ArH), 8.30 (2H, d, J 9.2, p-NO2ArH).
2,2-dimethylpropionyloxymethyl p-nitrophenyl Carbonate (2)
Figure US06703522-20040309-C00013
Carbonate 2 was also prepared as described in the above paper (1.16 g, 60%).
νmax(film)/cm−1 1779, 1759 (C═O), 1530 (C═C, Ar).
δH(400 MHz; CDCl3) 1.26 (9H, s, tbutyl), 5.89 (2H, s, OCH2O), 7.41 (2H, d, J 9.4, p-NO2ArH), 8.30 (2H, d, J 9.2, p-NO2ArH).
Benzoyloxymethyl p-nitrophenyl Carbonate (3)
Figure US06703522-20040309-C00014
Carbonate 3 was also prepared as described in the above paper (1.76 g, 85%).
νmax(film)/cm−1 1778, 1740 (C═O), 1525 (C═C Ar).
δH(400 MHz; CDCl3) 6.14 (2H, s, OCH2O), 7.42 (2H, d, J 9.2, p-NO2ArH), 7.49 (2H, t, J 8.0, ArH), 7.64 (1H, t, J 7.6, ArH), 8.12 (2H, d, J 7.2, ArH) 8.29 (2H, d, J 9.2, p-NO2ArH).
The invention will now be further described with reference to the following Examples.
EXAMPLE 1
(S)-3-(Benzoylaminomethyl)-5-methylhexanoic Acid (4)
Benzoyl chloride (0.88 ml, 7.6 mmol) was added to a stirred suspension of pregabalin (1.0 g, 6.3 mmol) in THF (80 ml) at room temperature under argon and the reaction mixture was stirred for 18 hours. The reaction mixture was then filtered and concentrated in vacuo. The residue was chromatographed (SiO2, heptane-ethyl acetate, 1:1 to 3:7) to give 4 (0.78 g, 47%).
νmax(film)/cm−1 1705, 1634 (C═O), 1547 (C═C, Ar).
δH(400 MHz; CDCl3) 0.92 (3H, d, J 6.8, CH3), 0.94 (3H, d, J 7.6, CH3), 1.20-1.30 (2H, m, CH2CH(CH3)2), 1.69-1.79 (1H, m, CH(CH3)2), 2.20-2.30 (1H, m, CHCH2CH(CH3)2), 2.35 (1H, dd, J 8.1, 14.7, CHAHBCOOH), 2.45 (1H, dd, J 14.7, 4.2, CHAHBCOOH), 3.38-3.43 (1H, m, CHAHBNH), 3.57-3.63 (1H, m, CHAHBNH), 6.63 (1H, bs, NH), 7.41-7.57 (3H, m, ArH), 7.78 (2H, d, J 7.6, ArH).
EXAMPLE 2
(S)-Benzyl 3-(benzoylaminomethyl)-5-methylhexanoate (5)
Benzyl alcohol (0.31 g, 3.0 mmol) was added to a stirred mixture of (S)-3-(benzoylaminomethyl)-5-methylhexanoic acid 4 (0.78 g, 3.0 mmol), 1,3-dicyclo-hexylcarbodiimide (0.61 g, 3.0 mmol), and 4-dimethylaminopyridine (0.36 g, 3.0 mmol) in dichloromethane (40 ml) and the mixture was stirred for 18 hours. The reaction mixture was, filtered and concentrated in vacuo. The residue was chromatographed (SiO2, heptane-ether, 1:0 to 75:25) to give 5(0.83 g, 79%).
νmax(film)/cm−1 1732, 1640 (C═O).
δH(400 MHz; CDCl3) 0.89 (3H, d, J 7.2, CH3), 0.91 (3H, d, J 6.8, CH3), 1.19-1.30 (2H, m, CH2CH(CH3)2), 1.64-1.75 (1H, m, CH(CH3)2)2.23-2.35 (1H, m, CHCH2CH(CH3)2), 2.39 (1H, dd, J 15.4, 7.3 , CHAHBCOOH), 2.47(1H, dd, J 15.4, 4.9, CHAHBCOOH), 3.34-3.39 (1H, m, CHAHBNH), 3.52-3.58 (1H, m, CHAHBNH), 5.08 (2H, s, ArCH2O), 6.64 (1H, bt, NH), 7.27-7.38 (5H, m, ArH), 7.39-7.50 (3H, m, ArH), 7.75 (2H, d, J 7.2, ArH).
EXAMPLE 3
(S)-3-[N-(acetoxymethyleneoxycarbonyl)aminomethyl]-5-methylhexanoic Acid (6)
The carbonate 1 (1.0 g, 3.9 mmol) and pregabalin (0.62 g, 3.9 mmol) were stirred in THF (60 ml) at room temperature for 48 hours. The reaction mixture was taken up in ethyl acetate (250 ml) and washed with water (200 ml), 1N HCl (200 ml), dried (MgSO4) and concentrated in vacuo. The residue was purified by column chromatography (SiO2, heptane, then heptane-ethyl acetate, 1:1) to give (6) (0.18 g, 17%).
νmax(film)/cm−1 1715 (C═O).
δH(400 MHz; CDCl3) 0.91 (3H, d, J 6.8, CH3), 0.91 (3H, d, J 6.8, CH3), 1.10-1.30 (2H, m, CH2CH(CH3)2), 1.60-1.71 (1H, m, CH(CH3)2), 2.12 (3H, s, COCH3), 2.15-2.35 (1H, m, CHCH2CH(CH3)2), 2.27 (1H, dd, J 15.0, 8.0, CHAHBCOOH), 2.37 (1H, dd, J 14.8, 4.4, CHAHBCOOH), 3.10-3.17 (1H, m, CHHNH), 3.30-3.36 (1H, m, CHHNH), 5.28 (1H, bs, NH), 5.71 & 5.75 (OCH2O).
From reagents 2 and 3 there may correspondingly be prepared (S)-3-[N-((2,2-dimethylpropionyloxymethylenoxy)carbonyl)aminomethyl)-5-methyl-hexanoic acid and (S)-3-[N-(benzoyloxymethyleneoxycarbonyl)aminomethyl]-5-methylhexanoic acid.

Claims (17)

What is claimed is:
1. A compound of the formula (IV)
Figure US06703522-20040309-C00015
in which:
R4 is hydrogen or a labile ester-forming group selected from substituted and unsubstiruted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body;
P is hydrogen or methyl;
Q is selected from
Figure US06703522-20040309-C00016
in which;
R7 is hydrogen, straight or branched chain C1-C6 alkyl, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and
X represents a phenyl group or any of the side chains of the 20 naturally encoded α-amino acids; or a pharmaceutically acceptable salt of any salt-forming compound within the above class.
2. A compound of the formula (III)
Figure US06703522-20040309-C00017
in which:
P is hydrogen or methyl;
R1 is straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;
R2 is hydrogen or methyl; and
R3 is hydrogen, methyl or carboxyl; and
R4 is hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body;
Q is selected from
Figure US06703522-20040309-C00018
in which:
R7 is hydrogen, straight or branched chain C1-C6 alkyl, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and
X represents a phenyl group or any of the side chains of the 20 naturally encoded α-amino acids; or
a pharmaceutically acceptable salt of any salt-forming compound within the above class, but excluding compounds in which R1 is phenyl and R2, R3 and R4 are each hydrogen.
3. The compound of claim 2, wherein Q is
Figure US06703522-20040309-C00019
wherein R7 is methyl, t-butyl or phenyl.
4. The compound of claim 1, wherein Q is
Figure US06703522-20040309-C00020
wherein R7 is methyl, t-butyl or phenyl.
5. A compound selected from
(S)-3-(Benzoylaminomethyl)-5-methylhexanoic acid;
(S)-Benzyl-3-(acylaminomethyl)-5-methylhexanoate;
(S)-3-[N-(acetoxymethylneoxycarbonyl)aminomethyl]-5-methylhexanoic acid;
(S)-3-[N-((2,2-dimethylpropionyloxy)methyleneoxycarbonyl)-amino-methyl]-5-methylhexanoic acid;
(S)-3-[N-(benzoyloxymethyleneoxycarbonyl)aminomethyl]-5-methyl-hexanoic acid; and
pharmaceutically acceptable salts of any of the above.
6. A method for making a compound of the formula (III) or salt thereof, as defined in claim 2, which comprises:
coupling a compound of the formula:
Figure US06703522-20040309-C00021
in which P and R1-R4 have the meanings given in claim 2 and in which said compound is in the form of a free base or an ammonium salt with a compound of the formula
Figure US06703522-20040309-C00022
or QCl where Q has the meaning given in claim 1.
7. The method of claim 6, in which the compound (V) is a carboxylic acid and comprising the further step of esterifying the carboxyl group with a substituted or unsubstituted C1-C6 alkanol, benzyl alcohol or phenol.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the formula (III)
Figure US06703522-20040309-C00023
in which:
P is hydrogen or methyl;
R1 is straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl;
R2 is hydrogen or methyl; and
R3 is hydrogen, methyl or carboxyl; and
R4 is hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body,
Q is selected from
Figure US06703522-20040309-C00024
in which:
R7 is hydrogen, straight or branched chain C1-C6 alkyl, phenyl or benzyl in which either or each benzene ring may be substituted or unsubstituted; and
X represents a phenyl group or any of the side chains of the 20 naturally encoded α-amino acids;
or a pharmaceutically acceptable salt of any salt-forming compound within the above class,
but excluding compounds in which R1 is phenyl and R2, R3 and R4 are each hydrogen.
9. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to claim 1 to a human or animal in need of said treatment.
10. A method for treating faintness attacks, hypokinesia and cranial disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a human or animal in need of said treatment.
11. A method for treating a neurodegenerative disorder comprising administering a therapeutically effective amount of a compound according to claim 1 to a human or animal in need of said treatment.
12. A method for treating depression comprising administering a therapeutically effective amount of a compound according to claim 1 to a human or animal in need of said treatment.
13. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to claim 2 to a human or animal in need of said treatment.
14. A method for treating panic comprising administering a therapeutically effective amount of a compound according to claim 2 to a human or animal in need of said treatment.
15. A method for treating pain comprising administering a therapeutically effective amount of a compound according to claim 2 to a human or animal in need of said treatment.
16. A method for treating a neuropathological disorder comprising administering a therapeutically effective amount of a compound according to claim 2 to a human or animal in need of said treatment.
17. A method for treating a digestive disorder corn rising administering a therapeutically effective amount of a compound according to claim 2 to a human or animal in need of said treatment.
US10/301,295 2000-08-01 2002-11-21 Alkyl amino acid derivatives useful as pharmaceutical agents Expired - Lifetime US6703522B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/301,295 US6703522B2 (en) 2000-08-01 2002-11-21 Alkyl amino acid derivatives useful as pharmaceutical agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0018828A GB2365425A (en) 2000-08-01 2000-08-01 Alkyl amino acid derivatives useful as pharmaceutical agents
GB0018828.4 2000-08-01
US09/920,215 US20020099092A1 (en) 2000-08-01 2001-08-01 Alkyl amino acid derivatives useful as pharmaceutical agents
US10/301,295 US6703522B2 (en) 2000-08-01 2002-11-21 Alkyl amino acid derivatives useful as pharmaceutical agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/920,215 Continuation US20020099092A1 (en) 2000-08-01 2001-08-01 Alkyl amino acid derivatives useful as pharmaceutical agents

Publications (2)

Publication Number Publication Date
US20030144214A1 US20030144214A1 (en) 2003-07-31
US6703522B2 true US6703522B2 (en) 2004-03-09

Family

ID=9896732

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/920,215 Abandoned US20020099092A1 (en) 2000-08-01 2001-08-01 Alkyl amino acid derivatives useful as pharmaceutical agents
US10/301,295 Expired - Lifetime US6703522B2 (en) 2000-08-01 2002-11-21 Alkyl amino acid derivatives useful as pharmaceutical agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/920,215 Abandoned US20020099092A1 (en) 2000-08-01 2001-08-01 Alkyl amino acid derivatives useful as pharmaceutical agents

Country Status (8)

Country Link
US (2) US20020099092A1 (en)
EP (1) EP1178034A1 (en)
JP (1) JP2002105038A (en)
BR (1) BR0104228A (en)
CA (1) CA2354342A1 (en)
GB (1) GB2365425A (en)
HK (1) HK1043785A1 (en)
MX (1) MXPA01007792A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
ATE540678T1 (en) * 2001-06-11 2012-01-15 Xenoport Inc GABA ANALOG PRODRUGS, COMPOSITIONS AND USES THEREOF
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2002100344A2 (en) 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
CN101381339B (en) * 2001-06-11 2012-03-07 什诺波特有限公司 Prodrugs of gaba analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003042162A1 (en) * 2001-11-17 2003-05-22 Neurosearch A/S Prodrugs of antidepressants and their use for treating depressions
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
PT1572173E (en) 2002-12-13 2010-05-10 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
NZ540591A (en) * 2002-12-13 2008-03-28 Warner Lambert Co Pregabalin derivatives for the treatment of fibromyalgia and other disorders
AU2004259659B2 (en) 2003-07-09 2011-11-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
AU2004259661B2 (en) * 2003-07-09 2011-11-10 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
CN101914040A (en) * 2003-08-20 2010-12-15 什诺波特有限公司 Acyloxyalkyl carbamate prodrugs, synthetic method and purposes
WO2005019163A2 (en) 2003-08-20 2005-03-03 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
CN1871021B (en) * 2003-09-17 2010-07-28 什诺波特有限公司 Treatment or prevention of restless legs syndrome with prodrugs of GABA analogues
RU2377234C2 (en) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Treatment or prevention of restless legs syndrome with using promedicines of gaba analogues
NZ546381A (en) 2003-10-14 2010-01-29 Xenoport Inc Crystalline form of gamma-aminobutyric acid analog
CN102702065A (en) 2003-12-30 2012-10-03 什诺波特有限公司 Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
RU2440112C2 (en) 2004-11-04 2012-01-20 Ксенопорт, Инк. Delayed-release oral dosage form of gabapentin
EA200970487A1 (en) * 2006-12-08 2009-12-30 Ксенопорт, Инк. APPLICATION OF GABA ANALOGUE PROCEDURES FOR TREATMENT OF DISEASES
CN101600458A (en) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 Combination therapy of lower urinary tract diseases with α2δ ligands and NSAIDs
EP1992609A1 (en) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid
US20090041806A1 (en) * 2007-06-15 2009-02-12 Xenoport, Inc. Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity
ITMI20072262A1 (en) * 2007-12-03 2009-06-04 Dipharma Francis Srl PROCEDURE FOR THE PREPARATION OF ACID (S) (+) - 3- (AMINOMETHYL) -5-METHYLESANOIC
FR2931151A1 (en) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si NOVEL AMINO ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
US20110130454A1 (en) * 2009-11-24 2011-06-02 Xenoport, Inc. Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
CN107050456B (en) 2010-09-28 2022-08-12 加利福尼亚大学董事会 GABA Agonists for the Treatment of Metabolic Syndrome Related Disorders and GABA Combinations for the Treatment or Prevention of Type I Diabetes
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
FR2997081B1 (en) * 2012-10-23 2015-11-27 Pharmaleads MIXED INHIBITORS OF N-AMINOPEPTIDASE AND NEPRILYSIN
EP3265074B1 (en) 2015-03-03 2020-08-12 ARK Diagnostics, Inc. Pregabalin immunoassays

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009957A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1999031074A2 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01319466A (en) * 1988-06-20 1989-12-25 Nippon Chemiphar Co Ltd Baclofen derivative and drug containing the same derivative
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009957A1 (en) * 1996-09-04 1998-03-12 Warner-Lambert Company Compounds for and a method of inhibiting matrix metalloproteinases
WO1999031074A2 (en) * 1997-12-16 1999-06-24 Warner-Lambert Company ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
Andruszkiewicz et al., 4-Amino-3-alkybutanoic acids as substrates for .gamma. -aminobutyric acid aminotransferase, Chemical Abstract No. 114:7161.
Andruszkiewicz et al., Chemoenzymatic synthesis of (R)-and (S)-4-amino-3-methylbutanoic acids, Chemical Abstract No. 113:41263.
Barluenga et al., Cycloaddition Reactions of Chiral 2-Amino-1,3-butadienes with Nitroalkenes: Synthesis of Enantiomerically Pure 4-Nitrocyclohexanones, Chemical Abstract No. 127:205290.
Brenner and Seebach, Enantioselective Preparation of gamma.-amino acids and .gamma.-lactams from nitro olefins and carboxylic acids, with the valins-derived 4-isopropyl-5,5-diphenyl-1,3-oxazolidin-2-one as an auxiliary, Chemical Abstract No. 132:194314.
Brenner et al, Helvetica Chimica Acta vol. 82, 1999 pp. 2365-2379.* *
Bryan et al., Facile synthesis of .beta.-substituted glutamic acids, Chemical Abstract No. 122.10509.
Co-pending U.S. application No. 09/254,093.
Co-pending U.S. application No. 10/009,938.
Dieter et al., (.alpha.-Aminoalkyl) cuprates Prepared from Soluble Copper (I) Salts: Conjugate Additions to .alpha., .beta.-Unsaturated Carboxylic Acid Derivatives, Chemical Abstract No. 127:33680.
El Achqar et al., 2-Hydroxy-3-pinanone as chiral auxiliary in the asymmetric synthesis of .alpha. -amino acids, Chemical Abstract No. 110:193343.
Great Britain Search Report GB 0018828.4.
Larue et al., Solution conformation of .alpha., .beta. or .gamma.-methylglutamyl-containing derivatives as probes of vitamin K-dependent carboxylase using molecular modeling and nuclear magnetic resonance, Chemical Abstract No. 127:118890.
Leenders et al., .beta.-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPT, Chemical Abstract No. 123:228716.
Sivov et al., Preparing (+)-or (-)-.beta.-phenyl-.gamma.-aminobutyric acid hydrochlorides, Chemical Abstract No. 95:203556.
Sivov et al., Preparing (+)—or (−)—.beta.-phenyl-.gamma.-aminobutyric acid hydrochlorides, Chemical Abstract No. 95:203556.
Slavinskaya et al Zh Org Zhin vol. 32, 1996 pp 1683-1684.* *
Slavinskaya et al., Synthesis of 4-amino-3-phenylburanohydroxamic acid, Chemical Abstract No. 126:277230.
Suzuki et al., thero-3-Alkyl- and -arylglutamic acid derivatives by Michael additions of Boc-BMI Li-enolates to 2, 6-di-tert-butyl-4-methoxyphenyl alkenoates on the diastereoselectivity of the coupling of trigonal centers involving heterocyclic Li-enolates, Chemical Abstract No. 116:84124.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease

Also Published As

Publication number Publication date
HK1043785A1 (en) 2002-09-27
GB0018828D0 (en) 2000-09-20
BR0104228A (en) 2002-04-09
US20020099092A1 (en) 2002-07-25
CA2354342A1 (en) 2002-02-01
MXPA01007792A (en) 2004-07-16
GB2365425A (en) 2002-02-20
EP1178034A1 (en) 2002-02-06
JP2002105038A (en) 2002-04-10
US20030144214A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
US6703522B2 (en) Alkyl amino acid derivatives useful as pharmaceutical agents
US20030216469A1 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
US6627771B1 (en) Gamma amino butyric and acid analogs
US6521650B1 (en) Amines as pharmaceutical agents
JP4913796B2 (en) Crystalline form of γ-aminobutyric acid analog
JP3744928B2 (en) Bicyclic amino acids as pharmaceutical formulations
EP1492761B1 (en) Amino acids with affinity for the alpha-2-delta-protein
KR20020009631A (en) Mono- and Disubstituted 3-Propyl Gamma-Aminobutyric Acids
US20030203945A1 (en) Heterocyclic derivatives useful as pharmaceutical agents
WO2020075023A2 (en) Compositions and methods for the treatment of parkinson's disease
JP5080458B2 (en) Compounds for the inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for the treatment of depression disorders, processes for their preparation and their use

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: WARNER-LAMBERT COMPANY LLC, NEW YORK

Free format text: ARTICLES OF ORGANIZATION-CONVERSION;ASSIGNOR:WARNER-LAMBERT COMPANY;REEL/FRAME:054306/0192

Effective date: 20021231

AS Assignment

Owner name: UPJOHN US 1 LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNER-LAMBERT COMPANY LLC;REEL/FRAME:054293/0956

Effective date: 20200801